Primaxin

(Imipenem)

ApprovedSmall molecule

Imipenem is an antibiotic used to treat serious bacterial infections in the hospital setting, including infections of the blood, lungs, abdomen, and urinary tract.[2] Primaxin is currently approved and in use across 17 indications[4].[1]

Primaxin is one of 375 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

374

Competitors

Pipeline

Status by Indication[4][1]

Indication

Acute PancreatitisActive, not recruiting

Bacterial DiseaseUnknown

AbscessActive, not recruiting

NeutropeniaActive, not recruiting

Bacterial PneumoniaActive, not recruiting

Lymphoid NeoplasmActive, not recruiting

BronchitisActive, not recruiting

PneumoniaUnknown

SepsisUnknown

EndocarditisUnknown

Acute PancreatitisApproved

Active, not recruiting

Bacterial DiseasePreclinical

Unknown

AbscessPhase 2/Phase 3

Active, not recruiting

NeutropeniaApproved

Active, not recruiting

Bacterial PneumoniaPhase 3

Active, not recruiting

Lymphoid NeoplasmPhase 2

Active, not recruiting

BronchitisApproved

Active, not recruiting

PneumoniaPreclinical

Unknown

SepsisPreclinical

Unknown

EndocarditisPreclinical

Unknown

Showing 10 of 17 indications

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Primaxin

Pfizer

Approved

2 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Retrovir

BBp Consulting, Inc

Preclinical

2 5

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Advil

KKenvue Brands

Preclinical

2 7

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2/3Recruiting

Abscess

NCT04310930

Clinical

Trials by Indication[1]

Pneumonia2 trials

Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia

Completed·PPrince of Songkla University·Phase 4·NCT01379157·8 enrolled

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

Completed· Pfizer logo

Pfizer·Phase 3·NCT00080496·430 enrolled

Septic Shock2 trials

The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients

Completed·SSoutheast University, China··NCT03308214·25 enrolled

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04208763·90 enrolled

Neutropenia2 trials

Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia

Completed·PPrince of Songkla University·Phase 4·NCT02213783·12 enrolled

Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

Completed·—·N/A·NCT01714570·123 enrolled

Cirrhosis1 trial

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01820026·96 enrolled

Bacterial Pneumonia1 trial

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02493764·537 enrolled

11 more indications

Acute Pancreatitis1 trial

Imipenem Prophylaxis in Patients With Acute Pancreatitis

Completed·UUniversity Hospital Rijeka·Phase 4·NCT02897206·98 enrolled

Antibiotics1 trial

Evaluation of Innovative Tools in Development of Antibiotics

Completed·MMedical University of Vienna·Phase 1·NCT03177720·10 enrolled

Ventilator-Associated Pneumonia1 trial

The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia

Completed·SSutep Jaruratanasirikul·Phase 4·NCT01489124·9 enrolled

Bronchitis1 trial

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Terminated·UUniversity Hospital, Lille·Phase 4·NCT03012360·103 enrolled

Hematological Malignancies1 trial

Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03733340·250 enrolled

Abscess1 trial

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting·TThe University of Queensland·Phase 2/3·NCT04310930·300 enrolled

Urinary Tract Infection1 trial

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Terminated·—·Phase 4·NCT02474706·6 enrolled

Outcome1 trial

PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

Unknown status·PPrince of Songkla University··NCT03858387·102 enrolled

Critically Ill Patients1 trial

Imipenem in Critically Ill Patients

Unknown status·PPrince of Songkla University·Phase 4·NCT03776305·12 enrolled

Statin1 trial

Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin

Unknown status·SSoutheast University, China·Phase 4·NCT02616354·24 enrolled

Antibiotic Prophylaxis1 trial

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Completed·NNorthwestern University·Phase 4·NCT01659866·563 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Imipenem. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Primaxin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Imipenem compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Imipenem. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bacterial Penicillin-Binding Protein Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Primaxin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Pneumonia2 trials

Septic Shock2 trials

Neutropenia2 trials

Cirrhosis1 trial

Bacterial Pneumonia1 trial

Acute Pancreatitis1 trial

Antibiotics1 trial

Ventilator-Associated Pneumonia1 trial

Bronchitis1 trial

Hematological Malignancies1 trial

Abscess1 trial

Urinary Tract Infection1 trial

Outcome1 trial

Critically Ill Patients1 trial

Statin1 trial

Antibiotic Prophylaxis1 trial

References

Drug Info

Quick Facts

Related News